Seres Therapeutics, Inc. Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share
Seres Therapeutics, Inc. (MCRB) reported Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share of $0.00 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare · last filed 2026-03-12
- Seres Therapeutics, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2025-06-30 was $0.00.
- Seres Therapeutics, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2025-03-31 was $0.00.
- Seres Therapeutics, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2024-09-30 was $18.32.
- Seres Therapeutics, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Seres Therapeutics, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2024 was $16.20, a 35.68% increase from fiscal 2023.
- Seres Therapeutics, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2023 was $11.94.
- Seres Therapeutics, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2022 was -$0.62.
| Period end | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 3 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 3 month as first filed | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 6 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 9 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 9 month as first filed | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 12 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | ||||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | |||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | ||||||
| 2024-12-31 | $16.20 10-K · filed 2026-03-12 | $0.81 10-K · filed 2025-03-13 | |||||
| 2024-09-30 | $18.32 10-Q · filed 2025-11-05 | $0.92 10-Q · filed 2024-11-13 | $16.78 10-Q · filed 2025-11-05 | $0.84 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | -$0.88 10-Q · filed 2025-08-06 | -$1.87 10-Q · filed 2025-08-06 | |||||
| 2024-03-31 | -$0.99 10-Q · filed 2025-05-07 | ||||||
| 2023-12-31 | $11.94 10-K · filed 2026-03-12 | $0.60 10-K · filed 2025-03-13 | |||||
| 2023-09-30 | -$0.05 10-Q · filed 2024-11-13 | $0.65 10-Q · filed 2024-11-13 | |||||
| 2022-12-31 | -$0.62 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |